{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"8.4","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The median progression-free survival time is defined as the time from registration to progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. Progression is defined using the Cheson et al. Revised Response Criteria for Malignant Lymphoma as: Any new lesion or increase by ≥50% of previously involved sites from nadir, Appearance of a new lesion(s) \\> 1.5 cm in any axis, ≥50% increase from nadir in SPD of more than one node, or ≥50% increase in longest diameter of a previously identified node \\> 1 cm in short axis, Lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy, \\> 50% increase from nadir in the SPD of any previous lesions, New or recurrent involvement.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral 40 mg panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (LBH589)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Every 6 months for up to 2 years","title":"Median Progression-free Survival Time","type":"SECONDARY","unitOfMeasure":"months"}